NCT07583160 — Changhai Hospital neoantigen vaccine trial
YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer
Registry record
| Registry ID | NCT07583160 ↗ |
|---|---|
| Lead sponsor | Changhai Hospital |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Enrolling By Invitation |
| Indication | Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC), Prostate Neoplasms |
| Enrollment | 18 participants (target) |
| Start date | 2026-06-01 |
| Primary completion | 2028-06-01 (est.) |
| Last registry update | 13 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07583160), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07583160?
NCT07583160 (YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by Changhai Hospital.
Is NCT07583160 recruiting?
As of the 2026-05-13 registry update, NCT07583160 is listed as "Enrolling By Invitation". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07583160?
The lead sponsor is Changhai Hospital.
What condition does NCT07583160 study?
The registered conditions are Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC), Prostate Neoplasms. Primary completion is listed as 2028-06-01 (estimated).
Are results available for NCT07583160?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07583160.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.